What question did this study set out to answer?

This research investigates the survival outcomes and treatment effectiveness of patients with transformed non-Hodgkin lymphoma after receiving rituximab.

September 20, 2013British Journal of HaematologyOpen Access

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

View Full Paper

Ask AI

Bookmark

Authors

MBMakiko Ban‐HoefenUniversity of Rochester Medical Center AVAnn VanderplasCity of Hope ACAllison Crosby‐ThompsonBrigham and Women's Hospital

Discussion

Member takes

Implication

Randomized trial analyzes survival outcomes in transformed non-Hodgkin lymphoma patients, highlighting treatment implications.

Key Points

This research investigates the survival outcomes and treatment effectiveness of patients with transformed non-Hodgkin lymphoma after receiving rituximab.
Multicenter database analysis using the NCCN outcomes database
Identified 118 patients with indolent non-Hodgkin lymphoma and histological transformation
Analytical comparisons between treatment groups: auto-SCT, allo-SCT, and non-transplant.
Overall survival for the cohort was 68% at 2 years.
Among patients aged ≤ 60, those who underwent auto-SCT had a 2-year OS of 74% (n=24).
Patients naïve to chemotherapy before transformation had a 100% 2-year OS compared to 35% for those previously exposed (P = 0.03).

Cite This Study

Ban‐Hoefen et al. (2013) studied this question.

synapsesocial.com/papers/6a62c6e9fcd714155f099c0e https://doi.org/10.1111/bjh.12570

View Full Paper

Ask AI

Bookmark

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

Discussion

Member takes

Implication

Key Points

Cite This Study

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider